Capital Stock (Details Narrative) (Mymd Pharmaceuticals Inc.) - $ / shares |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2020 |
Dec. 30, 2019 |
Dec. 31, 2018 |
|
| Common stock, shares authorized | 100,000,000 | 100,000,000 | ||
| Undesignated preferred stock | 50,000,000 | 50,000,000 | 50,000,000 | |
| Mymd Pharmaceuticals Inc. [Member] | ||||
| Common stock, shares authorized | 90,000,000 | 90,000,000 | ||
| Mymd Pharmaceuticals Inc. [Member] | Share Issuance [Member] | ||||
| Sale of stock price per share | $ 1.00 | $ 1.00 | ||
| Number of common stock issued, shares | 1,653,000 | |||
| Mymd Pharmaceuticals Inc. [Member] | Classes of Stock [Member] | ||||
| Capital stock, shares authorized | 100,000,000 | |||
| Common stock, shares authorized | 90,000,000 | |||
| Undesignated preferred stock | 10,000,000 |
| X | ||||||||||
- Definition Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|